Mallinckrodt to Settle FTC Monopoly Charges for $100 Million
Mallinckrodt will pay $100 million to settle FTC charges that the company maintained a U.S. monopoly for the only approved adrenocorticotropic hormone (ACTH) drug, Acthar, by acquiring the rights to a rival therapy, Synacthen.
Source: Drug Industry Daily